The immunological and main clinical features of pSS and PBC [8, 9].
\r\n\tMass spectrometry has a significant potential to further advance the clinical analysis and be a diagnostic tool for pathology or being used in the operation room and enable fast detection of tumor's margin.
\r\n\tThis book aims to provide an insight into different application fields of mass spectrometry for clinical research and routine. Modern mass spectrometry enables analysis and quantitation of very complex samples such as serum or tissue proteome or lipidome and the mass spectrometry imaging complements tissue analysis in pathology departments.
\r\n\tFurthermore, mass spectrometry can be used in an operating room as a device for on-site detection of tumor margins and be a valuable help for the surgeon.
\r\n\t
\r\n\tMass spectrometry imaging of tissue is an advanced type of tissue analysis that complements and aids the pathology and the traditional tissue analysis by staining and optical microscopy.
Epithelial tissue constitutes a barrier between organs and the environment. The epithelium lines external surfaces of internal organs and inner surfaces of the walls of blood vessels. It is also a tissue that exocrine and endocrine glands consist of.
\nAs they separate the organism from the outer environment, the epithelial structures form the first line of defense against external factors but, at the same time, an entry gate for them influencing the development of the body’s microbiome and autoimmune diseases, which are associated with the disorders of microbiome composition (dysbiosis) [1, 2]. The epithelium, also as a target for viruses, interacts with the invading pathogens and is actively involved in immune response, whose course depends on particular genetic and epigenetic conditions.
\nEpithelial cells are often subject to apoptosis, which makes them an important source of autoantigens. Moreover, in many autoimmune diseases, epithelial cells are damaged, which leads to further release and exposition of autoantigens, with the epithelium being subject to the immune response. For example, thyrocytes are responsible for providing the main immunogens (e.g., thyroglobulin, thyroid peroxidase, TSH receptor) in autoimmune thyroiditis [3], synoviocytes are a source of cyclic citrullinated peptides in rheumatoid arthritis, and oligodendrocytes in multiple sclerosis or pancreatic endocrine glandular epithelium (beta-cells) in type 1 diabetes are a source among others of proinsulin or glutamic acid decarboxylase [4]. Hence the suggestion puts forward that autoimmune diseases could be otherwise classified as the autoimmune inflammation of the epithelium [5]. However, there are autoimmune diseases which, due to their effect on the exocrine glands, are particularly associated with epithelial damage and an autoimmune process, the primary Sjögren’s syndrome (pSS) among them. The primary Sjögren’s syndrome is an autoimmune disease in which the exocrine glandular epithelium is a main source of autoantigens—such as Ro/SS-A and La/SS-B ribonucleoproteins [6]. Quite often pSS may coexist with another autoimmune disorder—a primary biliary cholangitis (PBC). In PBC the epithelium (biliary epithelial cells of small bile duct) is the starting point of the autoimmune process [7]. The pathogenesis of both diseases is similar, with the significant role of epithelial cell apoptosis. Table 1 presents the immunological and main clinical features of pSS and PBC.
\nPrimary Sjögren’s syndrome | \nPrimary biliary cholangitis | \n
---|---|
Exocrine glands | \nLiver | \n
Chronic autoimmune disease | \nChronic autoimmune disease | \n
Anti–SS-A and anti–SS-B antibodies | \nAnti-mitochondrial antibodies (AMA) | \n
ANA antibodies | \nANA antibodies may be present | \n
Exocrine glandular epithelium | \nBiliary epithelial cells | \n
Predominance of CD4+ infiltrate around the salivary duct | \nGranuloma and predominance of CD4+ infiltrate around the bile duct | \n
Woman > men | \nWoman > men | \n
Fifth decade of life | \nFifth decade of life | \n
Primary/secondary to other autoimmune diseases | \nPrimary/secondary to other autoimmune diseases | \n
Genetic factors—variability in genetic factors | \nGenetic factors—predominant role | \n
Infectious initiating factors: Herpesviridae particularly Epstein–Barr virus, CMV, herpes | \nInfectious initiating factors: Escherichia coli, Helicobacter pylori EBV | \n
Symptoms of eye and mouth dryness Extraglandular manifestations (organ impairment, vasculitis, neuropathy) | \nFatigue, pruritus, skin hyperpigmentation, hepatosplenomegaly Liver cirrhosis (late stage with ascites, jaundice, hepatic encephalopathy, upper digestive bleeding) | \n
Lymphoma | \nHepatocellular carcinoma | \n
EULAR/ACR criteria for diagnosis (2016) \n
Exclusions: | \nDiagnostic criteria for PBC \n
| \n
The Sjögren’s syndrome is an example of the development of an autoimmune epithelitis and consequences of such a process. The impact of environmental factors on the genetically susceptible subject is vital for the development of pSS. There are multiple genes (e.g., HLA-B8, HLA-Dw3, HLA-DR3, and DRw52) responsible for the individual’s susceptibility to the pSS development. Particular attention has been paid to the genes for interferon regulatory factor 5 (IRF5), signal transducer and activator of transcription 4 (STAT4) in the type I interferon (IFN) system, and B lymphocyte kinase (BLK) involved in B-cell activation, which are considered as risk loci in pSS development [10]. Additionally it has been recently revealed that also epigenetic mechanisms, such as DNA methylation, histone modifications, and noncoding RNAs, may influence expression of the involved genes in autoimmune diseases, including pSS [11].
\nThe pSS development is associated with the infection with viruses, which mainly target B cells or display tropism to lacrimal and salivary glands. Such a strong association has been confirmed in case of the Epstein–Barr virus, as well as other viruses: Cytomegalovirus, herpes simplex virus, and hepatitis C virus [12].
\nThe epithelitis in pSS starts with an influence of certain external factors, such as viruses, rare bacteria, or ultraviolet radiation on epithelial cells. This leads to cell apoptosis and expression of autoantigens (SS-A and SS-B ribonucleoproteins), which are presented to autoreactive T cells. As it is recently highlighted in the literature, endothelial cells have, therefore, antigen presentation properties, although this is not their main feature, as it is the case with antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells. Also salivary gland epithelial cells (SGEC) express MHC class I and MHC class II (HLA-DR) molecules and functional co-stimulator B7.1 (CD80) and B7.2 (CD86) molecules and may transmit signals to T lymphocytes as nonprofessional APCs [13, 14].
\nOther processes responsible for the development at this stage include the activation of the innate immune system, with the activation of Toll-like receptors (especially TLR3, TLR7, TLR9) and the production of interferon alpha (IFN-α) by plasma dendritic cells (pDCs) stimulating epithelial cells, dendritic cells, and neutrophils for the production of the B-cell stimulating factor and APRIL [15]. There are infiltrates in the exocrine glands initially composed mainly of T cells, whereas the activation of B lymphocytes by growth factors, such as BAFF and APRIL, results in hypergammaglobulinemia and the production of anti–SS-A and anti–SS-B autoantibodies as a secondary immune response. B cells and macrophages also produce proinflammatory cytokines, chemokines, and adhesion molecules.
\nThe disease starts with the epithelial inflammation and impaired function of the exocrine glands manifesting themselves, for example, in the enlargement of the glands and reduction of the secretion of saliva or tears. It evolves then into the phase of systemic disease with the organ involvement and general manifestations (fever, weight loss, fatigue). Although the Sjögren’s syndrome is most often associated with the functional impairment of lacrimal and salivary glands (symptoms included in the current criteria of diagnosis [16]), it also affects glands of the digestive system, pancreas, liver, gall bladder, respiratory glands, and even sweat glands. Their function is impaired through the reduction of secretion of the aqueous phase and changes in density of the secretion, leading to the emergence of various clinical features: from the feeling of mouth or eye dryness, through recurrent cholelithiasis and nephrolithiasis, to stones in the salivary glands.
\nThe consequence of the involvement of epithelia in pSS and its damage is the emergence of the way of entry for pathogens in the alimentary tract (from the oral cavity to the rectum), as well as in the respiratory tract. In the case of imbalance of the microbiome and the occurrence of dysbiosis, also commensals, which become potential pathogens in such circumstances, may cross the damaged epithelial barrier. Proteins from the epithelial cells of the mouth, intestines, and skin, as well as bacterial (commensal) proteins, may initiate an immune response to Ro60 (theory of Ro60-reactive B cells) and activation of T cells, as consequence of molecular mimicry [17]. The role of fungal (Candida) infections in pSS development was also studied, revealing there was no significant relationship between Candida albicans and the rate and amount of salivary secretion, although such relationship was found in pathogenic species, such as C. tropicalis, C. glabrata, and C. krusei [18].
\nIn Table 2 the main clinical manifestations of pSS resulting from the epithelial damage are presented.
\nLocalization | \nEffect | \n
---|---|
Nasal and oral cavity | \nOral candidiasis, dental caries, periodontitis otitis media, dry nose, chronic sinusitis, nasal bleeding, weakening of the sense of smell | \n
Bronchi | \nDifficulty in swallowing, dry cough, hoarseness, recurrent bronchitis and less frequent bronchioles, bronchial hyperresponsiveness and accompanying dry cough, infections | \n
Lungs | \nInterstitial lung disease | \n
Stomach | \nChronic gastritis, malabsorption, susceptibility to H. pylori infection | \n
Gut | \nCeliac disease, colitis Gluten sensitivity [19, 20] | \n
Liver | \nHepatitis, cholangitis | \n
Pancreas | \nPancreatitis | \n
Kidneys and urine tract | \nInterstitial nephritis with distal renal tubular acidosis (dRTA). Glomerulonephritis with coexisting cryoglobulinemia and urolithiasis | \n
The main clinical manifestations of pSS due to the epithelial damage.
Subtypes of lymphoma due to localization | \n\n | |
---|---|---|
MALT | \nNALT | \nNasopharynx-associated lymphoid tissue | \n
BALT | \nBronchus-associated lymphoid tissue | \n|
LALT | \nLarynx-associated lymphoid tissue | \n|
GALT | \nGut-associated lymphoid tissue | \n|
SALT | \nSkin-associated lymphoid tissue | \n|
CALT | \nConjunctiva-associated lymphoid tissue | \n|
SDALT | \nSalivary duct-associated lymphoid tissue | \n|
O-MALT | \nOrganized mucosa-associated lymphatic tissue-specific type of MALT affecting Waldeyer’s tonsillar ring | \n|
D-MALT | \nDiffuse mucosa-associated lymphatic tissue-specific type of the disease, cells not organized into a separate macroscopically and anatomically identifiable mass, but spread throughout the mucosa of different organs | \n
What is particularly important, continuous stimulation of B lymphocytes by activating agents, primarily BAFF and APRIL, causes germinal center (GC) formation and the formation of secondary lymphoid tissue, which in turn leads to the increased risk of lymphoma development. The most common lymphoma emerging in the course of pSS is the marginal zone B-cell lymphoma (MZBCL), the mucosa-associated lymphoid tissue (MALT) type being predominant. The diffuse large B-cell lymphoma (DLBCL), rare T-cell lymphoma, or NK-cell lymphoma are less common. The occurrence of MZBCL has been observed in about 8% of pSS patients; it is 40 times higher than in the healthy population [21, 22].
\nThe most important feature of MALT lymphoma is the presence of neoplastic cells (mainly B cells, as well as T cells) within epithelial structures, which may lead to destruction of the glandular architecture, also because of the formation of solid infiltrations.
\nLymphomas in pSS are predominantly localized in salivary glands, which has been confirmed in many studies [23], whereas in the general population, MALT lymphoma is most often located in the stomach. The occurrence of MALT lymphoma in the stomach is proven to be associated with H. pylori infection [24]. The primary division of MALT lymphomas depending on the location is shown in Table 3.
\n\n
Oral cavity\n
Saliva substitutes: hydroxymethylcellulose-containing oral spray, proper hydration by consuming more liquids, and regularly rinsing the mouth
The stimulation of salivary flow, obtained with the use of pilocarpine or cevimeline, parasympathomimetics, and muscarinic agonists affecting M1 and M3 receptors, after considering possible contraindications for their use.
\nAntifungal and antimicrobial treatment with medications such as chlorhexidine; the use of nonfluoride remineralizing agents as concomitant therapy.
\nDiet modification is recommended: eating slightly acidic products such as lemon, supplementing diet with unsaturated fatty acids (omega-3), and avoiding sweets and sweet effervescent beverages.
\nQuitting smoking is strongly recommended.\n
2. Dry eye\n
A. The modification of environmental factors, which may increase the dry eye symptoms, such as air condition, exposure to dust, and prolonged work at computer screen.
When possible, the discontinuation of treatment with medications resulting in the reduction of tears or disruption of their composition.
\nArtificial tears, gels, ointments, special contact lenses, topical autologous serum, and special contact lenses.
\nPunctual plugs (temporary or permanent).
\nThe eyelid therapy: massages and warm compresses.
\nThe eyelid surgery (e.g., blepharoplasty).
\nTopical immunosuppression: steroids and cyclosporine A.\n
3. Vaginal dryness
Vaginal dryness treatment is based on the use of intimate moisturizers and sexual lubricants and pH balance stabilizers free from hormones and skin irritants. In some cases the use of estrogen topical medication may be found useful.
\nImmunosuppressive drugs such as azathioprine, methotrexate, leflunomide, mycophenolic acid, cyclosporine A (topical, rare oral), and cyclophosphamide effects are used to inhibit general symptoms and organ involvement [26, 27].
\nAmong biological drugs, rituximab (anti-CD20 monoclonal antibody) has been showing positive results in current clinical trials and is used to inhibit certain aspects of the disease. Rituximab improves saliva flow rate and lacrimal gland function (discussed), diminishes fatigue and malaise, and is recommended in case of cryoglobulinemia or vasculitis-related peripheral nervous system involvement or other severe neurologic manifestations of this disease.
\nGlucocorticosteroids (GCS) are used in immunosuppressive therapy combined with other immunosuppressive drugs. Pulses of GCS are used in the case of the intensification of organ changes, vasculitis, and nervous system involvement.
\nIntravenous immunoglobulin administration and plasma exchanges are used in life-threatening cases of nervous system involvement and vasculitis.
\nOther: Vitamin D supplementation and aerobic exercises are recommended.
\nAntihistamines, e.g., loratadine or diphenhydramine, are used. Cholestyramine as the addition to beverages and foods may be used. Rifampicin, an antibiotic which may act as a medicine against itching, may also be administered [28]. Opioid antagonists containing naloxone or naltrexone inhibit pruritus by their effects on the central nervous system [29].
\nUrsodeoxycholic acid (UDCA) is the main medication used in biliary cholangitis. A complementary therapy with obeticholic acid was introduced in 2016, as second-line treatment. If the UDCA treatment is ineffective, the use of fibrates (e.g., bezafibrate) in combination therapy (UDCA plus fibrate) is also considered; ongoing clinical trials have yielded encouraging results [30]. Of the immunosuppressants, the use of methotrexate (MTX), as a drug which may affect pruritus score, serum level of alkaline phosphatase, or IgM level, is discussed [31], although there were observations that MTX could increase mortality in this group of patients [32]. There were clinical trials with rituximab [33] and with ustekinumab [34], but at the present time, they have not produced positive results to the expected extent. The liver transplant aims at prolonging the patient’s life, but it is reported that up to 29% of patients develop a relapse of the disease in the transplanted organ [35]. Therefore, the use of UDCA after transplantation is still recommended.
\nPBC is a chronic autoimmune liver disease in which a lifestyle is particularly important. Reducing the intake of foods with high sodium content, avoiding alcohol, as well as being careful with new medications or dietary supplements are extremely important. Physical exercise is recommended to reduce risk of bone loss and muscle weakness.
\nThe epithelium is an important element of the human body due to its protective, secretory, and transporting functions. It is also the target for the immunological processes. The impact of environmental, genetic, and epigenetic factors, leading to the epithelial cell damage/apoptosis, may cause a breakdown of epithelium hemostasis and the development of autoimmune diseases, Sjögren’s syndrome being its prominent representative. For years pSS was associated with autoimmune epithelial inflammation and referred to as the “autoimmune epithelitis.” However, the spectrum of diseases related to the epithelial autoimmunity is wider including, e.g., primary biliary cholangitis. The damaged epithelium is a source of autoantigens, and a persistent immune cell stimulation may lead to the lymphomas associated with the mucosa. Adoption of a wider perspective, combining the clinical experience and scientific knowledge, in an approach to the problem of epithelitis enables making the connection between emerging symptoms and autoimmune diseases, leading to the earlier diagnosis and introduction of proper treatment. Thus the reduction in an activity of the immune process and inhibition of further damage to the epithelium and of loss of its protective properties can be achieved.
\nAcute ischemic stroke (AIS) remains the second cause of death worldwide [1], despite showing a mortality rate reduction of 1.19% [2]; only in 2017, there were 6 million 167, 291 deaths; 1, 291,000 more with respect to 1997. During the same period, the survival rate increased by 0.02%; this caused an increment in the disability-adjusted life years percentage (DALYs), which went from 4.17 to 5.29% [2].
\nData from the World Health Organization (WHO) indicate that stroke represents the third cause of permanent adult disability worldwide [3], and is present in 90% of survivors. Motor deficits after stroke account for the high rates of long-lasting disability. The most common impairments are related to speech, or language and communication disorders (aphasia and dysphasia), apraxia [4], swallowing, depression, cognitive impairment, and hemiparesis of the contralateral limb [5] characterized by muscle weakness or spasticity in distal rather than proximal muscles [6]. These deficits ultimately cause chronic disability, affecting the ability to work and the patient’s independence and autonomy for performing daily life activities such as dressing or eating, ensuring they will require long-lasting care, which also deteriorates their quality of life and that of the patients’ caregivers.
\nStroke complications represent a considerable economic burden both individually and as a society; such complications are associated with a substantial increase in household expenses related to a higher requirement of medical attention, medication, lost workdays, and payment to external or additional caregivers, and in several cases, physical rehabilitation. It is estimated that the United States alone had an annual expenditure of 45.5 billion dollars during the 2014–2015 period, which is only expected to increase through 2035, according to estimations of RTI international [7].
\nIt is therefore fundamental to revisit the procedures regarding basic and clinical research points of view, as well as the most recent recommendations issued by the American Heart Association/American Stroke Association (AHA/ASA), which endorse multiple-component quality improvement initiatives including emergency department education and multidisciplinary teams with neurological management experience, thus increasing the application of fibrinolytic treatment IV.
\nThe strategies that are currently being studied in search of treatments for cerebral ischemia can be categorized into four areas: clinical care, neuroprotection, neurorestoration strategies, and rehabilitation therapy.
\nThe term neuroprotection is defined as the intentional intervention, either inhibition or modulation, that takes place at a certain point during the ischemic cascade, to intervene in a specific mechanism of damage to prevent tissue injury from increasing during the acute phase of ischemia [8]. The neurorestoration is developed through the stimulation of neurogenesis and neuroplasticity to restore the tissue and functional integrity of the neural tissue.
\nIn the clinical setting, several recanalization strategies have been explored to restore blood flow to the injured area of tissue as soon as possible, to assure the lesser damage and decrease secondary sequelae to the original lesion. Finally, physical therapy has become a rehabilitation tactic that has positively impacted the recovery of patients’ independence, autonomy, and quality of life, which is worth reviewing.
\nCerebral ischemia is caused by an abrupt and sustained occlusion of blood flow to a large artery that unties a series of biochemical alterations that are known as the ischemic cascade, Figure 1 [9]; during the development of such changes, a set of mechanisms that lead to cell death occurs: ionic imbalance and excitotoxicity, oxidative stress, and inflammation [10].
\nKey points to the pathophysiology of stroke.
The reduction of blood flow leads to a depletion in levels of glucose and O2, which alters aerobic metabolism, increasing lactic acid accumulation. Simultaneously, astrocytes use stored glycogen to provide energy to the neurons in the form of lactate [11]; but, because aerobic metabolism is interrupted at this time, lactic acid continues to accumulate, causing lactic acidosis, which causes ionic dysfunction [12]. Ionic alterations, together with Na+/K+ pump inactivity, give rise to neuronal depolarization, which leads to the opening of the Ca2+ channels and the subsequent release of excitatory neurotransmitters such as glutamate, causing increased activation of ionotropic receptors, especially NMDA, increasing the Ca2+ flux into the cell [13].
\nCa2+ is an essential protagonist within the ischemic cascade since it is capable of activating a significant amount of proteins that lead to cell death, and overproduction of free radicals; such proteins are calpains [14], endonucleases [15], calmodulin [16], and A2 phospholipase (Figure 1) [17]. Activation of these proteins leads to a further increase in free radical production and other oxidant species that directly damage structural molecules and activate inflammatory processes [18].
\nThe mitochondria are where the highest production of free radicals takes place; under normal conditions, superoxide anion (O2\n−) and hydrogen peroxide (H2O2) are produced continuously and eliminated by antioxidant enzymes such as superoxide dismutase (SOD), catalase, and glutathione peroxidase [19]. Alternatively, under ischemic conditions, reperfusion provides sufficient substrate for different enzymatic oxidation reactions to take place, causing an overproduction of free oxygen radicals (ROS) and the inactivation of antioxidant enzymes [20]. Concurrently, nitric oxide (NO) increases due to the activation of endothelial and neuronal nitric oxide synthases as a result of increased Ca2+ concentration, NO reacts with ROS and forms a highly toxic peroxynitric acid (ONOOH) [21].
\nFree radicals promote mitochondrial membrane permeability and allow for cytochrome c to be released into the cytosol, where the intrinsic pathway of apoptosis becomes activated, the concentration of free radicals also increases lipid peroxidation and protein denaturalization [22], DNA fragmentation, and activate several signaling pathways that lead to neural death, such as PI3K/AKT [23], Bcl2, p53 [24] and others. From the moment of the occlusion, endothelial cells express damage-associated molecular patterns (DAMPs), produce ROS and adhesion molecules that allow for their activation and that of surrounding mast cells and macrophages, which, as a consequence, release histamine, proteases, TNF-a, and chemokines [25]. The production and release of these molecules promote the blood-brain barrier (BBB) rupturing, thus causing peripheral leukocyte invasion into the injured brain parenchyma [26].
\nMicroglial cells are then activated in the non-perfused region of the brain parenchyma [27], microglial cells acquire phagocytic characteristics and a predominantly pro-inflammatory phenotype (M1), which in turn increases the release of interleukin-6 (IL-6), interleukin 1β (IL-1β), tumor necrosis factor-alpha (TNF-α), NO molecules, and prostanoids [28]. Peripheral immune cells such as neutrophils, B lymphocytes, T lymphocytes, and NK are recruited into the injured tissue, this event is thought to contribute both beneficially by inducing the release of anti-inflammatory cytokines and growth factors, and negatively by increasing the lesion through a sustained release of proinflammatory cytokines and free radicals [29].
\nWithin the process of the ischemic cascade, three points are identified that could classify as strategic to restore neuroprotection (ionic imbalance, excitotoxicity, and inflammation); nonetheless, most neuroprotective drugs act in many of the phases of the ischemic cascade, which is why they cannot be classified into a single step of neuroprotection.
\nEarly diagnosis of stroke is a predictor for better clinical outcomes [30]; therefore, its confirmation is a pressing matter for the treatment to begin as soon as possible from the recognition of symptoms onset [31]. Currently, different strategies for acute ischemic stroke are being used in the clinical setting and are part of the AHA/ASA clinical practice guidelines [32].
\nThe differential diagnosis for stroke includes transient ischemic attacks, seizure, syncope, migraine, and brain tumors [33]. To establish a correct and timely diagnosis and to determine the best course of action, the clinician must rely on laboratory testing [34] (blood glucose is usually high, total cholesterol, LDL, HDL, AST, CPK-MB), and although the gold standard for diagnosis is a cerebral angiography, clinicians try to avoid it by choosing different methods such as imaging testing, including the first-line non-contrast CT scans, CT angiography, MRI, and MRI angiography [32, 35, 36]. In the earliest stages of acute stroke, CT scans are less useful for ischemic stroke diagnosis but can rule out hemorrhagic stroke [36]. Other clinical tests such as EKG, EEG, and the National Institutes of Health Stroke Scale (NIHSS) help establish differential diagnosis and treatment plan [35].
\nSpecific and timely reperfusion treatment is essential to determine the course of the clinical outcome and to improve survival. Once the ischemic etiology has been established, and the patient is stable, treatment should start promptly. Currently, two major therapeutic strategies are being used to treat cerebral ischemia to allow for recanalization and reperfusion. The treatment of choice will depend on time to treatment and etiology of the injury; these therapies are thrombolysis using pharmacological agents and mechanical thrombectomy [35, 37, 38, 39].
\nAt present and still after decades, the FDA only approves the use of recombinant tissue plasminogen activator (rTPA), also known as alteplase, as the sole pharmacological option for recanalization [35, 39]. Alteplase initiates local fibrinolysis when administered intravenously by hydrolyzing the peptide bond in plasminogen to form plasmin [40]. The standard IV dosage is 0.9 mg/kg for 60 min, with a 10% bolus over 1 min within 4.5 h of AIS onset [31].
\nAlthough alteplase is the only drug available for thrombolysis, most stroke sufferers do not receive this drug as treatment. There usually is a delay in recognition of the symptoms and the time window in which rTPA must be administered is from 3 to 4.5 h from onset of symptoms, and benefits diminish over time [39, 41], which is why the new AHA/ASA guidelines recommend not waiting for clinical improvement before administration [32]. Also, not all patients are eligible, since candidates must be ≤80 years of age, without diabetes or stroke history, with an NIHSS score ≤ 25, not currently taking oral anticoagulation, and without radiologic evidence of ischemic injury involving more than one-third of the MCA territory [42].
\nComplications that are associated with its use are limited: BBB integrity alterations, and hemorrhagic transformation, granting that other studies have shown it to be well tolerated by patients using warfarin or other anticoagulants [38], in controversy with the new AHA/ASA guidelines that suggest it should not be administered if the patient received heparin 24 h before [32, 35, 43]. Other drugs are also available, such as aspirin, which must be delivered within 24–48 h after stroke onset. Although the guidelines emphasize that it should not be used to replace mechanical thrombectomy or IV alteplase, aspirin continues to be the choice for secondary prophylaxis [32, 44], even when the 2018 guidelines find no benefit from its use for the treatment of an ongoing AIS [32].
\nFurthermore, the FDA approves of endovascular treatments, which are reported to have a time window of up to 8 hours from the onset of symptoms [38].
\nFor patients with large vessel occlusion, less responsive to rTPA, intra-arterial therapy is recommended, since it leads to higher recanalization rates by being able to infuse the drug directly into the occluded area or the clot itself [35, 45]. About 10% of patients with AIS fall into this category, but only a few centers can perform endovascular procedures in proper conditions [46].
\nAlso, endovascular mechanical thrombectomy using contact aspiration (CA) [47], which has been described before [48], and stent retrievers (SR), especially those of new generations [49], for clot rupturing and aspiration has shown significant benefits in large vessel occlusion [50] regarding clinical outcomes and lower complication rates [49]. Notwithstanding, CA alone, without the use of a SR, is associated with a greater need for rescue treatment, and thus, worse outcomes [51]; the SR might also increase the risk for hemorrhagic transformation and neurological deficit [52].
\nIncreased costs of endovascular treatments, as well as their complexity and need for trained personnel, cause patients to have less access to them. Therefore, exploring new pharmacological therapies should be continued.
\nIn the search to find new alternatives of neuroprotective agents, a great variety of molecules have been explored that affect one or several strategic points of the pathophysiology, and that promise good results; some are mentioned below.
\nDuring the onset of AIS, glucose and oxygen concentrations decrease, and this promotes the activation of adenosine monophosphate-activated protein kinase (AMPK). This process upregulates cellular pathways that control energy metabolism through catabolic pathways such as glycolysis and lipid oxidation to increase adenosine triphosphate (ATP) production and decrease its consumption through the inhibition of gluconeogenesis. Observations have been made regarding the fact that the activation of this enzyme for short periods increases neural survival, but its activation for extended periods will lead to cell death through apoptosis, necrosis, and autophagy [53], which is why several drugs that modulate AMPK activation have been tested recently in search for beneficial effects.
\nTo mention some, metformin has been widely studied for cerebral ischemia since it possesses pleiotropic activity and modulates AMPK activation [54]. In 2016, Zhang et al. administered 7 mg/kg of metformin intraperitoneally to C57BL/6 mice for 7 days, before middle cerebral artery occlusion (MCAO). After MCAO, the authors observed that it induced neuroprotection by reducing infarct size, through lower AMPK, results that were not observed if administered for short periods of 1–3 days before MCAO, or after the occlusion; also, these benefits were not found in the case of reperfusion [55]. Also, the neuroprotective effect of metformin was observed in a global ischemia model in rats; after administration, apoptosis decreased, and mitochondrial biogenesis was induced [56]. Other experiments have demonstrated that metformin has the potential to improve memory and learning through the increase in brain-derived neurotrophic factor (BDNF) and p7056k protein [57]. On the other hand, it has also been implicated in the reduction of IL-6, IL-1β, TNF-α, and adhesion molecule levels, as well as a decrease in neutrophil infiltration [58]. Considering these results, it is crucial to clarify how this modulation is carried out since there is some controversy about the mechanism (Table 1).
\nMain neuroprotective agents in ischemia.
\n
Atorvastatin is a statin that has pleiotropic effects, since it allows angiogenesis and synaptogenesis, increases blood flow, blunts atherosclerotic plaque formation, and provides neuroprotection in cerebral ischemia model [59] by reducing aquaporin 4 expression (AQP4) [60], thus, preventing cerebral edema and the increase of infarct size. This statin has also been reported to attenuate cognitive deficit [61] through caspase 3 inhibition and avoiding neural death in the CA1 region of the hippocampus.
\nThere is also a great variety of neuroprotective drugs or molecules that act closer by modulating inflammation, through the promotion of an anti-inflammatory microglial phenotype activation; only the most representative will be mentioned below.
\nDRα1 recombinant protein linked to the MOG peptide has demonstrated the ability to decrease macrophage migration and monocyte activation through its binding to CD74, which translates to a reduction in infarct size [62]. It has also been shown that it reduces proinflammatory cytokine expression, such as IL-1β, I-17, TNF-α, and INF-ϒ, as well as lowers T lymphocyte infiltration and promotes a polarization toward an M2 phenotype macrophage activation [63].
\nCop-1 or glatiramer acetate is a copolymer formed by four amino acids (L-alanine, L-lysine, L-glutamic, and L-tyrosine) that has shown to exert neuroprotective effects by being able to reduce infarct size and improve neurological deficit [64]. Cop-1 increases the expression of IL-10, BDNF, Insulin-like growth factor-1 (IGF-1), and neurotrophin (NT-3) in the choroid plexus [65], and the cortex, which stimulates greater neurogenesis [66]. Mangin et al. and their study group obtained similar results; they reported that Cop-1 is capable of reducing COX-2, CD32, TNF-α, and IL-1β, as well as inducing greater neurogenesis and thus, reducing memory loss in mice with cerebral ischemia [67].
\nOn the other hand, food strategies have also been proposed; for example, diet-induced ketosis has demonstrated its neuroprotective effects. Xu et al. observed, in 2017, that the ketogenic diet induced a reduction in infarct size through the overexpression of transcription factors HIF-1α, pAKT, and AMPK [68]; in 2018 Stefanovic, beneficial effects of administering exogenous β-hydroxybutyrate intraperitoneally were also observed in a model of cerebral ischemia induced by endothelin-1 in rats. He reported that the ischemic penumbra cells had a diminished glucose uptake, which translated into less ROS production, astrogliosis, and neuronal death [69]. Ketone bodies or ketosis is worth further exploration since clinical trials in Alzheimer’s patients with mild cognitive decline have shown improvements in verbal memory after being treated with a ketogenic diet [73].
\nDietary administration with docosahexaenoic acid (DHA) has also proven to have anti-inflammatory and neuroprotective effects in cerebral ischemia through the reduction of proinflammatory cytokine expression, such as TNF-α, IL-1β and IL-6; even, a decrease in macrophage and microglial activation and a decrease in leukocyte infiltration to the lesion site [70]. Similar observations were made by Cai et al. who noted that macrophage, neutrophil, and T and B lymphocyte infiltration was significantly decreased, besides stimulating an anti-inflammatory macrophage (M2) activation [71]; DHA is also capable of inducing neurogenesis and angiogenesis [72], which makes it a promising molecule for future experimental research.
\nMany of the cytokines and growth factors that result from immunomodulation processes are directly involved in neurorestoration processes, the latter understood as the set of strategies that seek to reconstruct the affected neural circuits through neuroplasticity or neurogenesis [74].
\nNeurotrophins are a group of proteins that are involved in the maintenance and survival of the central nervous system [75]; this includes BDNF, NT-3, NT-4, NT-5, nerve growth factor (NGF), and IGF-1. Neurotrophins interact with two types of receptors, Trk (tyrosine kinase receptors) and the p75 receptor that belongs to the TNFR receptor family, implicated in apoptosis processes.
\nAmong the most studied neurotrophins are BDNF and NT-3; BDNF is produced by almost all brain cells and is known to participate in processes of proliferation, survival, and neuronal differentiation. Its receptors are widely distributed [76] and activate critical signaling pathways such as PLCγ, PI3K, and ERK, which ultimately lead to phosphorylation and activation of the transcription factor CREB that mediates the expression of genes that are essential for the survival and differentiation of neurons [77]. NT-3 has also been involved in the processes of cell proliferation and differentiation through the notch pathway [78], as well as participating in processes of memory and learning [76].
\nExperiments have shown that the increase of neurotrophic factors in the ischemia model is commonly related to a better functional or memory recovery and that it is usually associated with neurogenesis or neuroplasticity—as in the case of metformin, which showed an increase in BDNF expression and that induced a more significant recovery of memory and learning [57]. Also, Cop-1 was able to induce the increase of BDNF, IGF-1, and NT-3; which correlated with the increase in neurogenesis [65]; and the experiments of Luan et al. showed that patients with cerebral ischemia who presented higher levels of NGF obtained a better functional recovery at 3 months after the ischemia [79].
\nStem cell transplantation has also been linked to better neurological recovery; although clinical trials have not reported the expected results [80], basic research using stem cells has shown an increase in neurological rehabilitation and suggested mechanisms include the overexpression of BDNF and IGF-1 [81, 82], as well as immunomodulatory cytokines like IL-10, which together induce a polarization toward an anti-inflammatory M2 microglial phenotype [83].
\nIn recent years, there has been an increase in the interest of studying how the external environment has a direct effect on the structure and neuronal function, that is, on neuroplasticity [84], and that is why researchers keep studying what kind of external characteristics (specifically physical and social activity) can increase these factors and thereby obtain more significant benefits.
\nIn 2017, Chen et al. explored whether a specific type of environment stimulated the production of BDNF in rats with cerebral ischemia, and what they observed was that physical stimulation increases the expression of neurotrophic factors more than social stimulation and obtains a higher neurological recovery [85]. Mang, on the other hand, observed that the increase in BDNF after an ischemic event is determined by the type of aerobic exercise and the val66met variant of the BDNF gene [86].
\nThe effects on NT-3 have also been evaluated, and the results have been very similar; there is an increase in its levels with physical stimulation after the ischemic event and a more significant functional recovery [87]. Other proteins have also been associated with neuronal plasticity through axonal growth, such as the growth-associated protein 43 (GAP-43), which has been observed to increase when rats with cerebral ischemia undergo fastigial electrostimulation [88].
\nElectrical stimulation directly into the fastigial nucleus (FNS) has proven to be beneficial in a model of MCAO [89]. The mechanism through which FNS has shown to improve walking balance and neurological scores is due to the activation of the PKA/cAMP pathway, suppressing the expression of Rho-Kinase, and through the overexpression of GAP-43 protein [89].
\nIn this sense, experiments continue to be designed to establish the efficacy of training types and times to modulate inflammation, the production of neurotrophins, and the impact on patient mobility, as in the proposal developed by Scalzo et al. [89] that gives rise to the continued development of a well-founded physical therapy for patients with cerebral ischemia.
\nPost-stroke physical rehabilitation (PR) is of utmost importance as a non-pharmacological strategy for neuroprotection and neurorestoration but, most significantly, should be aimed at restoring and regaining motor impairment during the chronic period [90], and to promote the functional autonomy of the patient [4]. Recovery of body function assessment depends on whether the patients can perform everyday activities on their own and is measurable by several different scales such as UE-FM score for the upper extremity, and the Barthel Index for Activities for Daily Living scale [4].
\nFunctional and cognitive deficit severity is related to tissue integrity [91], and it is not clear whether recovery results from biological processes or physical rehabilitation [91, 92]. Some clinical parameters that can be observed at the bedside, such as early finger extension and shoulder abduction, can act as predictors of long-term (over 6 months) recovery after stroke [93]. Spontaneous recovery of upper and lower limbs occurs depending on the type, location, and severity of the lesion, in approximately 60–70% of cases [93] during the first 2–6 months [4, 94], period after which most people believe they have achieved maximal recovery and stop with either physical or pharmacological therapy [4, 95]. Interventions should be designed according to the stage of neurological recovery the patient is in, with the consideration that early chronicity is not a contraindication for continuing rehabilitation [4].
\nPhysical rehabilitation must start early, if possible, during the first week post-stroke [96], because there is an intensification in neuroplasticity during the early stages [91], employing different mechanisms such as the axon regeneration [88], and the higher expression of growth-promoting genes, such as GAP-43. This lesion-induced plasticity that happens during the first days post-stroke [90, 97, 98] reportedly lasts around 6 months after stroke [4, 91, 95, 97]. Also, therapy must continue after such a period, to take advantage of behavior-induced plasticity [95], which is still possible after 1 year of having had the stroke [4].
\nPR has also been proven to elicit neuroprotection and neurorestoration in other neurological disease models, such as Parkinson’s, through the upregulation of BDNF and GDNF and prevention of inflammatory response [99]. The following therapies are currently under study for neurorestorative purposes during the post-stroke chronic period:
\nEnvironmental enrichment focuses on inducing adaptation to different environments, including toys and complex tasks, to improve functional outcomes [97]. Also, this type of therapy has shown to enhance angiogenesis by increasing CD31 and VEGF [97]. Furthermore, environmental enrichment upregulates BDNF secretion, and other neurotrophic factors [85, 90].
\nWang et al. found improvements in spatial learning and memory, number of synapses, and an increase in the expression of synaptogenesis markers. GAP-43, a protein involved in neural plasticity through axonal growth, is upregulated during the first 28 days after stroke in mice exposed to environmental enrichment. Likewise, other markers involved in synaptogenesis like SYN and PSD-95 achieve better concentrations in the brains of mice treated with environmental enrichment [97].
\nFunctional electrical therapy has been used alongside other types of electrical stimulation to induce repetitive muscular contraction to mobilize certain joints [6]. Somatosensory stimulation might enhance neurorehabilitation after stroke through the stimulation of corticomotoneuronal excitability [6]. It has been proposed that this type of therapy increases muscle strength, reduces spasticity, and facilitates voluntary movements, among other motor benefits [6].
\nGuided self-rehabilitation (GSR) is a method in which the intensity of training can be increased inside the home environment. While combined with conventional rehabilitation, it has proven to be efficacious in engaging the patients in their recovery through a contract between the patient and the therapist, allowing for an increased sense of responsibility and motivation for the patients, who are required to register their progress in a diary [100]. Although not many physical therapists accept such an approach [100], positive changes have been observed after 1 year of GSR and conventional rehabilitation in ultrasound measuring of the soleus’ and medial gastrocnemius’ thickness and fascicle length, as well as clinical improvement, observed in soleus extensibility and ambulation speed [101] in chronic stroke patients.
\nConstraint-induced therapy requires constraining the non-affected limb for 90% of the waking hours, forcing the patient to use the paretic limb, inducing the increase of use-dependent plasticity, although this therapy is not practical for most of the population [6].
\nVideogame- or virtual reality-based (VRb) therapies have been under study for upper extremity functional recovery in acute and subacute or chronic patients [91, 96, 99, 102]; the rationale for such approaches is that they promote motor learning and repetitive, intense movements, and in the specific case of virtual reality, the patient is exposed to interactive visual, auditive, and proprioceptive feedback [91, 102]. Different videogame and VRb therapies have reported improvements in fine dexterity, grip strength [96], and grasp force [99] in upper extremities, and, activities of daily living [91] and cognition [102] in young and elderly patients after several weeks of rehabilitation. Better results have been observed when combined with conventional therapy, although it is still not known whether it enhances or speeds up recovery [91].
\nIn addition to continuing the search for pharmacological agents that allow the neuroprotection and neurorestoration of tissue affected by cerebral ischemia, the development of physical therapy and diet modification offers new horizons that have shown satisfactory results in the clinical setting in short times. However, it has not yet been possible to establish a protocolized treatment that can be added to the health care guidelines; so it is important to continue exploring all possible strategies to improve the quality of life of people who have suffered a cerebral infarction and that of their caregivers.
\nLicense
\n\nBook Chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0). IntechOpen maintains a very flexible Copyright Policy that ensures that there is no copyright transfer to the publisher. Therefore, Authors retain exclusive copyright to their work. All Monographs are distributed under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
\n\n',metaTitle:"Open Access Statement",metaDescription:"Book chapters published in edited volumes are distributed under the Creative Commons Attribution 3.0 Unported License (CC BY 3.0)",metaKeywords:null,canonicalURL:"/page/open-access-statement/",contentRaw:'[{"type":"htmlEditorComponent","content":"Formats
\\n\\nBased on your preferences and the stage of your scientific projects, you have multiple options for publishing your scientific research with IntechOpen:
\\n\\nPeer Review Policies
\\n\\nAll scientific Works are subject to Peer Review prior to publishing.
\\n\\n\\n\\nCosts
\\n\\nThe Open Access publishing model followed by IntechOpen eliminates subscription charges and pay-per-view fees, thus enabling readers to access research at no cost to themselves. In order to sustain these operations, and keep our publications freely accessible, we levy an Open Access Publishing Fee on all manuscripts accepted for publication to help cover the costs of editorial work and the production of books.
\\n\\n\\n\\nDigital Archiving Policy
\\n\\nIntechOpen is dedicated to ensuring the long-term preservation and availability of the scholarly research it publishes.
\\n"}]'},components:[{type:"htmlEditorComponent",content:'Formats
\n\nBased on your preferences and the stage of your scientific projects, you have multiple options for publishing your scientific research with IntechOpen:
\n\nPeer Review Policies
\n\nAll scientific Works are subject to Peer Review prior to publishing.
\n\n\n\nCosts
\n\nThe Open Access publishing model followed by IntechOpen eliminates subscription charges and pay-per-view fees, thus enabling readers to access research at no cost to themselves. In order to sustain these operations, and keep our publications freely accessible, we levy an Open Access Publishing Fee on all manuscripts accepted for publication to help cover the costs of editorial work and the production of books.
\n\n\n\nDigital Archiving Policy
\n\nIntechOpen is dedicated to ensuring the long-term preservation and availability of the scholarly research it publishes.
\n'}]},successStories:{items:[]},authorsAndEditors:{filterParams:{sort:"featured,name"},profiles:[{id:"6700",title:"Dr.",name:"Abbass A.",middleName:null,surname:"Hashim",slug:"abbass-a.-hashim",fullName:"Abbass A. Hashim",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/6700/images/1864_n.jpg",biography:"Currently I am carrying out research in several areas of interest, mainly covering work on chemical and bio-sensors, semiconductor thin film device fabrication and characterisation.\nAt the moment I have very strong interest in radiation environmental pollution and bacteriology treatment. The teams of researchers are working very hard to bring novel results in this field. I am also a member of the team in charge for the supervision of Ph.D. students in the fields of development of silicon based planar waveguide sensor devices, study of inelastic electron tunnelling in planar tunnelling nanostructures for sensing applications and development of organotellurium(IV) compounds for semiconductor applications. I am a specialist in data analysis techniques and nanosurface structure. I have served as the editor for many books, been a member of the editorial board in science journals, have published many papers and hold many patents.",institutionString:null,institution:{name:"Sheffield Hallam University",country:{name:"United Kingdom"}}},{id:"54525",title:"Prof.",name:"Abdul Latif",middleName:null,surname:"Ahmad",slug:"abdul-latif-ahmad",fullName:"Abdul Latif Ahmad",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"20567",title:"Prof.",name:"Ado",middleName:null,surname:"Jorio",slug:"ado-jorio",fullName:"Ado Jorio",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Universidade Federal de Minas Gerais",country:{name:"Brazil"}}},{id:"47940",title:"Dr.",name:"Alberto",middleName:null,surname:"Mantovani",slug:"alberto-mantovani",fullName:"Alberto Mantovani",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"12392",title:"Mr.",name:"Alex",middleName:null,surname:"Lazinica",slug:"alex-lazinica",fullName:"Alex Lazinica",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/12392/images/7282_n.png",biography:"Alex Lazinica is the founder and CEO of IntechOpen. After obtaining a Master's degree in Mechanical Engineering, he continued his PhD studies in Robotics at the Vienna University of Technology. Here he worked as a robotic researcher with the university's Intelligent Manufacturing Systems Group as well as a guest researcher at various European universities, including the Swiss Federal Institute of Technology Lausanne (EPFL). During this time he published more than 20 scientific papers, gave presentations, served as a reviewer for major robotic journals and conferences and most importantly he co-founded and built the International Journal of Advanced Robotic Systems- world's first Open Access journal in the field of robotics. Starting this journal was a pivotal point in his career, since it was a pathway to founding IntechOpen - Open Access publisher focused on addressing academic researchers needs. Alex is a personification of IntechOpen key values being trusted, open and entrepreneurial. Today his focus is on defining the growth and development strategy for the company.",institutionString:null,institution:{name:"TU Wien",country:{name:"Austria"}}},{id:"19816",title:"Prof.",name:"Alexander",middleName:null,surname:"Kokorin",slug:"alexander-kokorin",fullName:"Alexander Kokorin",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/19816/images/1607_n.jpg",biography:"Alexander I. Kokorin: born: 1947, Moscow; DSc., PhD; Principal Research Fellow (Research Professor) of Department of Kinetics and Catalysis, N. Semenov Institute of Chemical Physics, Russian Academy of Sciences, Moscow.\r\nArea of research interests: physical chemistry of complex-organized molecular and nanosized systems, including polymer-metal complexes; the surface of doped oxide semiconductors. He is an expert in structural, absorptive, catalytic and photocatalytic properties, in structural organization and dynamic features of ionic liquids, in magnetic interactions between paramagnetic centers. The author or co-author of 3 books, over 200 articles and reviews in scientific journals and books. He is an actual member of the International EPR/ESR Society, European Society on Quantum Solar Energy Conversion, Moscow House of Scientists, of the Board of Moscow Physical Society.",institutionString:null,institution:{name:"Semenov Institute of Chemical Physics",country:{name:"Russia"}}},{id:"62389",title:"PhD.",name:"Ali Demir",middleName:null,surname:"Sezer",slug:"ali-demir-sezer",fullName:"Ali Demir Sezer",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/62389/images/3413_n.jpg",biography:"Dr. Ali Demir Sezer has a Ph.D. from Pharmaceutical Biotechnology at the Faculty of Pharmacy, University of Marmara (Turkey). He is the member of many Pharmaceutical Associations and acts as a reviewer of scientific journals and European projects under different research areas such as: drug delivery systems, nanotechnology and pharmaceutical biotechnology. Dr. Sezer is the author of many scientific publications in peer-reviewed journals and poster communications. Focus of his research activity is drug delivery, physico-chemical characterization and biological evaluation of biopolymers micro and nanoparticles as modified drug delivery system, and colloidal drug carriers (liposomes, nanoparticles etc.).",institutionString:null,institution:{name:"Marmara University",country:{name:"Turkey"}}},{id:"61051",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:null},{id:"100762",title:"Prof.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"St David's Medical Center",country:{name:"United States of America"}}},{id:"107416",title:"Dr.",name:"Andrea",middleName:null,surname:"Natale",slug:"andrea-natale",fullName:"Andrea Natale",position:null,profilePictureURL:"//cdnintech.com/web/frontend/www/assets/author.svg",biography:null,institutionString:null,institution:{name:"Texas Cardiac Arrhythmia",country:{name:"United States of America"}}},{id:"64434",title:"Dr.",name:"Angkoon",middleName:null,surname:"Phinyomark",slug:"angkoon-phinyomark",fullName:"Angkoon Phinyomark",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/64434/images/2619_n.jpg",biography:"My name is Angkoon Phinyomark. I received a B.Eng. degree in Computer Engineering with First Class Honors in 2008 from Prince of Songkla University, Songkhla, Thailand, where I received a Ph.D. degree in Electrical Engineering. My research interests are primarily in the area of biomedical signal processing and classification notably EMG (electromyography signal), EOG (electrooculography signal), and EEG (electroencephalography signal), image analysis notably breast cancer analysis and optical coherence tomography, and rehabilitation engineering. I became a student member of IEEE in 2008. During October 2011-March 2012, I had worked at School of Computer Science and Electronic Engineering, University of Essex, Colchester, Essex, United Kingdom. In addition, during a B.Eng. I had been a visiting research student at Faculty of Computer Science, University of Murcia, Murcia, Spain for three months.\n\nI have published over 40 papers during 5 years in refereed journals, books, and conference proceedings in the areas of electro-physiological signals processing and classification, notably EMG and EOG signals, fractal analysis, wavelet analysis, texture analysis, feature extraction and machine learning algorithms, and assistive and rehabilitative devices. I have several computer programming language certificates, i.e. Sun Certified Programmer for the Java 2 Platform 1.4 (SCJP), Microsoft Certified Professional Developer, Web Developer (MCPD), Microsoft Certified Technology Specialist, .NET Framework 2.0 Web (MCTS). I am a Reviewer for several refereed journals and international conferences, such as IEEE Transactions on Biomedical Engineering, IEEE Transactions on Industrial Electronics, Optic Letters, Measurement Science Review, and also a member of the International Advisory Committee for 2012 IEEE Business Engineering and Industrial Applications and 2012 IEEE Symposium on Business, Engineering and Industrial Applications.",institutionString:null,institution:{name:"Joseph Fourier University",country:{name:"France"}}},{id:"55578",title:"Dr.",name:"Antonio",middleName:null,surname:"Jurado-Navas",slug:"antonio-jurado-navas",fullName:"Antonio Jurado-Navas",position:null,profilePictureURL:"https://mts.intechopen.com/storage/users/55578/images/4574_n.png",biography:"Antonio Jurado-Navas received the M.S. degree (2002) and the Ph.D. degree (2009) in Telecommunication Engineering, both from the University of Málaga (Spain). He first worked as a consultant at Vodafone-Spain. From 2004 to 2011, he was a Research Assistant with the Communications Engineering Department at the University of Málaga. In 2011, he became an Assistant Professor in the same department. From 2012 to 2015, he was with Ericsson Spain, where he was working on geo-location\ntools for third generation mobile networks. Since 2015, he is a Marie-Curie fellow at the Denmark Technical University. His current research interests include the areas of mobile communication systems and channel modeling in addition to atmospheric optical communications, adaptive optics and statistics",institutionString:null,institution:{name:"University of Malaga",country:{name:"Spain"}}}],filtersByRegion:[{group:"region",caption:"North America",value:1,count:5703},{group:"region",caption:"Middle and South America",value:2,count:5174},{group:"region",caption:"Africa",value:3,count:1690},{group:"region",caption:"Asia",value:4,count:10246},{group:"region",caption:"Australia and Oceania",value:5,count:889},{group:"region",caption:"Europe",value:6,count:15653}],offset:12,limit:12,total:117317},chapterEmbeded:{data:{}},editorApplication:{success:null,errors:{}},ofsBooks:{filterParams:{topicId:"17"},books:[],filtersByTopic:[{group:"topic",caption:"Agricultural and Biological Sciences",value:5,count:9},{group:"topic",caption:"Biochemistry, Genetics and Molecular Biology",value:6,count:14},{group:"topic",caption:"Business, Management and Economics",value:7,count:2},{group:"topic",caption:"Chemistry",value:8,count:6},{group:"topic",caption:"Computer and Information Science",value:9,count:10},{group:"topic",caption:"Earth and Planetary Sciences",value:10,count:4},{group:"topic",caption:"Engineering",value:11,count:16},{group:"topic",caption:"Environmental Sciences",value:12,count:2},{group:"topic",caption:"Immunology and Microbiology",value:13,count:4},{group:"topic",caption:"Materials Science",value:14,count:5},{group:"topic",caption:"Mathematics",value:15,count:1},{group:"topic",caption:"Medicine",value:16,count:57},{group:"topic",caption:"Neuroscience",value:18,count:1},{group:"topic",caption:"Pharmacology, Toxicology and Pharmaceutical Science",value:19,count:5},{group:"topic",caption:"Physics",value:20,count:2},{group:"topic",caption:"Psychology",value:21,count:3},{group:"topic",caption:"Robotics",value:22,count:1},{group:"topic",caption:"Social Sciences",value:23,count:3},{group:"topic",caption:"Technology",value:24,count:1},{group:"topic",caption:"Veterinary Medicine and Science",value:25,count:2}],offset:12,limit:12,total:0},popularBooks:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8697",title:"Virtual Reality and Its Application in Education",subtitle:null,isOpenForSubmission:!1,hash:"ee01b5e387ba0062c6b0d1e9227bda05",slug:"virtual-reality-and-its-application-in-education",bookSignature:"Dragan Cvetković",coverURL:"https://cdn.intechopen.com/books/images_new/8697.jpg",editors:[{id:"101330",title:"Dr.",name:"Dragan",middleName:"Mladen",surname:"Cvetković",slug:"dragan-cvetkovic",fullName:"Dragan Cvetković"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:12,limit:12,total:5146},hotBookTopics:{hotBooks:[],offset:0,limit:12,total:null},publish:{},publishingProposal:{success:null,errors:{}},books:{featuredBooks:[{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9208",title:"Welding",subtitle:"Modern Topics",isOpenForSubmission:!1,hash:"7d6be076ccf3a3f8bd2ca52d86d4506b",slug:"welding-modern-topics",bookSignature:"Sadek Crisóstomo Absi Alfaro, Wojciech Borek and Błażej Tomiczek",coverURL:"https://cdn.intechopen.com/books/images_new/9208.jpg",editors:[{id:"65292",title:"Prof.",name:"Sadek Crisostomo Absi",middleName:"C. Absi",surname:"Alfaro",slug:"sadek-crisostomo-absi-alfaro",fullName:"Sadek Crisostomo Absi Alfaro"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"7831",title:"Sustainability in Urban Planning and Design",subtitle:null,isOpenForSubmission:!1,hash:"c924420492c8c2c9751e178d025f4066",slug:"sustainability-in-urban-planning-and-design",bookSignature:"Amjad Almusaed, Asaad Almssad and Linh Truong - Hong",coverURL:"https://cdn.intechopen.com/books/images_new/7831.jpg",editors:[{id:"110471",title:"Dr.",name:"Amjad",middleName:"Zaki",surname:"Almusaed",slug:"amjad-almusaed",fullName:"Amjad Almusaed"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9343",title:"Trace Metals in the Environment",subtitle:"New Approaches and Recent Advances",isOpenForSubmission:!1,hash:"ae07e345bc2ce1ebbda9f70c5cd12141",slug:"trace-metals-in-the-environment-new-approaches-and-recent-advances",bookSignature:"Mario Alfonso Murillo-Tovar, Hugo Saldarriaga-Noreña and Agnieszka Saeid",coverURL:"https://cdn.intechopen.com/books/images_new/9343.jpg",editors:[{id:"255959",title:"Dr.",name:"Mario Alfonso",middleName:null,surname:"Murillo-Tovar",slug:"mario-alfonso-murillo-tovar",fullName:"Mario Alfonso Murillo-Tovar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}},{type:"book",id:"9139",title:"Topics in Primary Care Medicine",subtitle:null,isOpenForSubmission:!1,hash:"ea774a4d4c1179da92a782e0ae9cde92",slug:"topics-in-primary-care-medicine",bookSignature:"Thomas F. Heston",coverURL:"https://cdn.intechopen.com/books/images_new/9139.jpg",editors:[{id:"217926",title:"Dr.",name:"Thomas F.",middleName:null,surname:"Heston",slug:"thomas-f.-heston",fullName:"Thomas F. Heston"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],latestBooks:[{type:"book",id:"7434",title:"Molecular Biotechnology",subtitle:null,isOpenForSubmission:!1,hash:"eceede809920e1ec7ecadd4691ede2ec",slug:"molecular-biotechnology",bookSignature:"Sergey Sedykh",coverURL:"https://cdn.intechopen.com/books/images_new/7434.jpg",editedByType:"Edited by",editors:[{id:"178316",title:"Ph.D.",name:"Sergey",middleName:null,surname:"Sedykh",slug:"sergey-sedykh",fullName:"Sergey Sedykh"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8545",title:"Animal Reproduction in Veterinary Medicine",subtitle:null,isOpenForSubmission:!1,hash:"13aaddf5fdbbc78387e77a7da2388bf6",slug:"animal-reproduction-in-veterinary-medicine",bookSignature:"Faruk Aral, Rita Payan-Carreira and Miguel Quaresma",coverURL:"https://cdn.intechopen.com/books/images_new/8545.jpg",editedByType:"Edited by",editors:[{id:"25600",title:"Prof.",name:"Faruk",middleName:null,surname:"Aral",slug:"faruk-aral",fullName:"Faruk Aral"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9569",title:"Methods in Molecular Medicine",subtitle:null,isOpenForSubmission:!1,hash:"691d3f3c4ac25a8093414e9b270d2843",slug:"methods-in-molecular-medicine",bookSignature:"Yusuf Tutar",coverURL:"https://cdn.intechopen.com/books/images_new/9569.jpg",editedByType:"Edited by",editors:[{id:"158492",title:"Prof.",name:"Yusuf",middleName:null,surname:"Tutar",slug:"yusuf-tutar",fullName:"Yusuf Tutar"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9839",title:"Outdoor Recreation",subtitle:"Physiological and Psychological Effects on Health",isOpenForSubmission:!1,hash:"5f5a0d64267e32567daffa5b0c6a6972",slug:"outdoor-recreation-physiological-and-psychological-effects-on-health",bookSignature:"Hilde G. Nielsen",coverURL:"https://cdn.intechopen.com/books/images_new/9839.jpg",editedByType:"Edited by",editors:[{id:"158692",title:"Ph.D.",name:"Hilde G.",middleName:null,surname:"Nielsen",slug:"hilde-g.-nielsen",fullName:"Hilde G. Nielsen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"7802",title:"Modern Slavery and Human Trafficking",subtitle:null,isOpenForSubmission:!1,hash:"587a0b7fb765f31cc98de33c6c07c2e0",slug:"modern-slavery-and-human-trafficking",bookSignature:"Jane Reeves",coverURL:"https://cdn.intechopen.com/books/images_new/7802.jpg",editedByType:"Edited by",editors:[{id:"211328",title:"Prof.",name:"Jane",middleName:null,surname:"Reeves",slug:"jane-reeves",fullName:"Jane Reeves"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8063",title:"Food Security in Africa",subtitle:null,isOpenForSubmission:!1,hash:"8cbf3d662b104d19db2efc9d59249efc",slug:"food-security-in-africa",bookSignature:"Barakat Mahmoud",coverURL:"https://cdn.intechopen.com/books/images_new/8063.jpg",editedByType:"Edited by",editors:[{id:"92016",title:"Dr.",name:"Barakat",middleName:null,surname:"Mahmoud",slug:"barakat-mahmoud",fullName:"Barakat Mahmoud"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"10118",title:"Plant Stress Physiology",subtitle:null,isOpenForSubmission:!1,hash:"c68b09d2d2634fc719ae3b9a64a27839",slug:"plant-stress-physiology",bookSignature:"Akbar Hossain",coverURL:"https://cdn.intechopen.com/books/images_new/10118.jpg",editedByType:"Edited by",editors:[{id:"280755",title:"Dr.",name:"Akbar",middleName:null,surname:"Hossain",slug:"akbar-hossain",fullName:"Akbar Hossain"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9157",title:"Neurodegenerative Diseases",subtitle:"Molecular Mechanisms and Current Therapeutic Approaches",isOpenForSubmission:!1,hash:"bc8be577966ef88735677d7e1e92ed28",slug:"neurodegenerative-diseases-molecular-mechanisms-and-current-therapeutic-approaches",bookSignature:"Nagehan Ersoy Tunalı",coverURL:"https://cdn.intechopen.com/books/images_new/9157.jpg",editedByType:"Edited by",editors:[{id:"82778",title:"Ph.D.",name:"Nagehan",middleName:null,surname:"Ersoy Tunalı",slug:"nagehan-ersoy-tunali",fullName:"Nagehan Ersoy Tunalı"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"9961",title:"Data Mining",subtitle:"Methods, Applications and Systems",isOpenForSubmission:!1,hash:"ed79fb6364f2caf464079f94a0387146",slug:"data-mining-methods-applications-and-systems",bookSignature:"Derya Birant",coverURL:"https://cdn.intechopen.com/books/images_new/9961.jpg",editedByType:"Edited by",editors:[{id:"15609",title:"Dr.",name:"Derya",middleName:null,surname:"Birant",slug:"derya-birant",fullName:"Derya Birant"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"8686",title:"Direct Torque Control Strategies of Electrical Machines",subtitle:null,isOpenForSubmission:!1,hash:"b6ad22b14db2b8450228545d3d4f6b1a",slug:"direct-torque-control-strategies-of-electrical-machines",bookSignature:"Fatma Ben Salem",coverURL:"https://cdn.intechopen.com/books/images_new/8686.jpg",editedByType:"Edited by",editors:[{id:"295623",title:"Associate Prof.",name:"Fatma",middleName:null,surname:"Ben Salem",slug:"fatma-ben-salem",fullName:"Fatma Ben Salem"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}]},subject:{topic:{id:"1083",title:"Medical Oncology",slug:"medical-oncology",parent:{title:"Oncology",slug:"medicine-oncology"},numberOfBooks:15,numberOfAuthorsAndEditors:436,numberOfWosCitations:226,numberOfCrossrefCitations:131,numberOfDimensionsCitations:346,videoUrl:null,fallbackUrl:null,description:null},booksByTopicFilter:{topicSlug:"medical-oncology",sort:"-publishedDate",limit:12,offset:0},booksByTopicCollection:[{type:"book",id:"8025",title:"Cancer Immunotherapy and Biological Cancer Treatments",subtitle:null,isOpenForSubmission:!1,hash:"e9953ff7bc3b22ae75810e286dd86b73",slug:"cancer-immunotherapy-and-biological-cancer-treatments",bookSignature:"Hilal Arnouk",coverURL:"https://cdn.intechopen.com/books/images_new/8025.jpg",editedByType:"Edited by",editors:[{id:"76431",title:"Dr.",name:"Hilal",middleName:null,surname:"Arnouk",slug:"hilal-arnouk",fullName:"Hilal Arnouk"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"6127",title:"Cancer Causing Substances",subtitle:null,isOpenForSubmission:!1,hash:"174eb39b8b0e84934f4a958e6d4de827",slug:"cancer-causing-substances",bookSignature:"Faik Atroshi",coverURL:"https://cdn.intechopen.com/books/images_new/6127.jpg",editedByType:"Edited by",editors:[{id:"65639",title:"Dr.",name:"Faik",middleName:null,surname:"Atroshi",slug:"faik-atroshi",fullName:"Faik Atroshi"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4756",title:"New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis",subtitle:null,isOpenForSubmission:!1,hash:"3d0f53df3dd15a086df1fc78bd2aaed7",slug:"new-aspects-in-molecular-and-cellular-mechanisms-of-human-carcinogenesis",bookSignature:"Dmitry Bulgin",coverURL:"https://cdn.intechopen.com/books/images_new/4756.jpg",editedByType:"Edited by",editors:[{id:"93072",title:"Dr.",name:"Dmitry",middleName:null,surname:"Bulgin",slug:"dmitry-bulgin",fullName:"Dmitry Bulgin"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"4537",title:"Updates on Cancer Treatment",subtitle:null,isOpenForSubmission:!1,hash:"e4d069af27b0dd4f600d1ae75aee66cd",slug:"updates-on-cancer-treatment",bookSignature:"Leticia B. A. Rangel and Ian Victor Silva",coverURL:"https://cdn.intechopen.com/books/images_new/4537.jpg",editedByType:"Edited by",editors:[{id:"60359",title:"Dr.",name:"Letícia",middleName:null,surname:"Rangel",slug:"leticia-rangel",fullName:"Letícia Rangel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3462",title:"Neoadjuvant Chemotherapy",subtitle:"Increasing Relevance in Cancer Management",isOpenForSubmission:!1,hash:"4f88a3fde61b5535375bde00b9c13d1e",slug:"neoadjuvant-chemotherapy-increasing-relevance-in-cancer-management",bookSignature:"Maurie M. Markman",coverURL:"https://cdn.intechopen.com/books/images_new/3462.jpg",editedByType:"Edited by",editors:[{id:"162295",title:"Dr.",name:"Maurie",middleName:null,surname:"Markman",slug:"maurie-markman",fullName:"Maurie Markman"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3273",title:"Cancer Treatment",subtitle:"Conventional and Innovative Approaches",isOpenForSubmission:!1,hash:"cdd9872a05001212b3583bff95bae979",slug:"cancer-treatment-conventional-and-innovative-approaches",bookSignature:"Letícia Rangel",coverURL:"https://cdn.intechopen.com/books/images_new/3273.jpg",editedByType:"Edited by",editors:[{id:"60359",title:"Dr.",name:"Letícia",middleName:null,surname:"Rangel",slug:"leticia-rangel",fullName:"Letícia Rangel"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3002",title:"Oncogenomics and Cancer Proteomics",subtitle:"Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer",isOpenForSubmission:!1,hash:"bc8990331803d9e6084b367163dcf218",slug:"oncogenomics-and-cancer-proteomics-novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer",bookSignature:"César López-Camarillo and Elena Aréchaga-Ocampo",coverURL:"https://cdn.intechopen.com/books/images_new/3002.jpg",editedByType:"Edited by",editors:[{id:"40928",title:"Dr.",name:"Cesar",middleName:null,surname:"Lopez-Camarillo",slug:"cesar-lopez-camarillo",fullName:"Cesar Lopez-Camarillo"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"3291",title:"T-Cell Leukemia",subtitle:"Characteristics, Treatment and Prevention",isOpenForSubmission:!1,hash:"fb2dc976b5929dc5fa310da0c658e55e",slug:"t-cell-leukemia-characteristics-treatment-and-prevention",bookSignature:"Mariko Tomita",coverURL:"https://cdn.intechopen.com/books/images_new/3291.jpg",editedByType:"Edited by",editors:[{id:"49567",title:"Dr.",name:"Mariko",middleName:null,surname:"Tomita",slug:"mariko-tomita",fullName:"Mariko Tomita"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"2610",title:"Carcinogenesis",subtitle:null,isOpenForSubmission:!1,hash:"61e4a760de592236762035553ff855e9",slug:"carcinogenesis",bookSignature:"Kathryn Tonissen",coverURL:"https://cdn.intechopen.com/books/images_new/2610.jpg",editedByType:"Edited by",editors:[{id:"145170",title:"Dr.",name:"Kathryn",middleName:null,surname:"Tonissen",slug:"kathryn-tonissen",fullName:"Kathryn Tonissen"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1898",title:"Cancer Management",subtitle:null,isOpenForSubmission:!1,hash:"877784b1af60471e118fade16d5c50d1",slug:"cancer-management",bookSignature:"Doaa Hashad",coverURL:"https://cdn.intechopen.com/books/images_new/1898.jpg",editedByType:"Edited by",editors:[{id:"110869",title:"Dr.",name:"Doaa",middleName:null,surname:"Hashad",slug:"doaa-hashad",fullName:"Doaa Hashad"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1756",title:"Carcinogen",subtitle:null,isOpenForSubmission:!1,hash:"4ec4fd67f39ca00211fc40e7b563d684",slug:"carcinogen",bookSignature:"Margarita Pesheva, Martin Dimitrov and Teodora Stefkova Stoycheva",coverURL:"https://cdn.intechopen.com/books/images_new/1756.jpg",editedByType:"Edited by",editors:[{id:"115544",title:"Dr.",name:"Margarita",middleName:null,surname:"Pesheva",slug:"margarita-pesheva",fullName:"Margarita Pesheva"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}},{type:"book",id:"1001",title:"Tumor Microenvironment and Myelomonocytic Cells",subtitle:null,isOpenForSubmission:!1,hash:"a2392066cd104cd48f3b296bf72b97a6",slug:"tumor-microenvironment-and-myelomonocytic-cells",bookSignature:"Subhra K. Biswas",coverURL:"https://cdn.intechopen.com/books/images_new/1001.jpg",editedByType:"Edited by",editors:[{id:"69842",title:"Dr.",name:"Subhra",middleName:"K.",surname:"Biswas",slug:"subhra-biswas",fullName:"Subhra Biswas"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter",authoredCaption:"Edited by"}}],booksByTopicTotal:15,mostCitedChapters:[{id:"44364",doi:"10.5772/55795",title:"Hyperthermia: Cancer Treatment and Beyond",slug:"hyperthermia-cancer-treatment-and-beyond",totalDownloads:3175,totalCrossrefCites:17,totalDimensionsCites:34,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Ahmed Bettaieb, Paulina K. Wrzal and Diana A. Averill-Bates",authors:[{id:"61148",title:"Prof.",name:"Diana",middleName:null,surname:"Averill-Bates",slug:"diana-averill-bates",fullName:"Diana Averill-Bates"},{id:"62367",title:"Dr.",name:"Ahmed",middleName:null,surname:"Bettaieb",slug:"ahmed-bettaieb",fullName:"Ahmed Bettaieb"},{id:"62368",title:"Dr.",name:"Paulina",middleName:null,surname:"K. Wrzal",slug:"paulina-k.-wrzal",fullName:"Paulina K. Wrzal"}]},{id:"24601",doi:"10.5772/22656",title:"Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies",slug:"combination-chemotherapy-in-cancer-principles-evaluation-and-drug-delivery-strategies",totalDownloads:4370,totalCrossrefCites:1,totalDimensionsCites:31,book:{slug:"current-cancer-treatment-novel-beyond-conventional-approaches",title:"Current Cancer Treatment",fullTitle:"Current Cancer Treatment - Novel Beyond Conventional Approaches"},signatures:"Ana Catarina Pinto, João Nuno Moreira and Sérgio Simões",authors:[{id:"48598",title:"Prof.",name:"Sergio",middleName:null,surname:"Simoes",slug:"sergio-simoes",fullName:"Sergio Simoes"},{id:"54753",title:"Dr.",name:"Ana",middleName:null,surname:"Pinto",slug:"ana-pinto",fullName:"Ana Pinto"},{id:"54754",title:"Prof.",name:"Joăo",middleName:null,surname:"Moreira",slug:"joao-moreira",fullName:"Joăo Moreira"}]},{id:"43632",doi:"10.5772/53110",title:"The Importance of Cancer Cell Lines as in vitro Models in Cancer Methylome Analysis and Anticancer Drugs Testing",slug:"the-importance-of-cancer-cell-lines-as-in-vitro-models-in-cancer-methylome-analysis-and-anticancer-d",totalDownloads:4189,totalCrossrefCites:12,totalDimensionsCites:31,book:{slug:"oncogenomics-and-cancer-proteomics-novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer",title:"Oncogenomics and Cancer Proteomics",fullTitle:"Oncogenomics and Cancer Proteomics - Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer"},signatures:"Daniela Ferreira, Filomena Adega and Raquel Chaves",authors:[{id:"155129",title:"Prof.",name:"Raquel",middleName:null,surname:"Chaves",slug:"raquel-chaves",fullName:"Raquel Chaves"},{id:"157394",title:"M.Sc.",name:"Daniela",middleName:"Perneta",surname:"Ferreira",slug:"daniela-ferreira",fullName:"Daniela Ferreira"},{id:"157395",title:"Dr.",name:"Filomena",middleName:null,surname:"Adega",slug:"filomena-adega",fullName:"Filomena Adega"}]}],mostDownloadedChaptersLast30Days:[{id:"42589",title:"Anticancer Properties of Cardiac Glycosides",slug:"anticancer-properties-of-cardiac-glycosides",totalDownloads:3270,totalCrossrefCites:2,totalDimensionsCites:5,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Varisa Pongrakhananon",authors:[{id:"60007",title:"Prof.",name:"Varisa",middleName:null,surname:"Pongrakhananon",slug:"varisa-pongrakhananon",fullName:"Varisa Pongrakhananon"}]},{id:"44364",title:"Hyperthermia: Cancer Treatment and Beyond",slug:"hyperthermia-cancer-treatment-and-beyond",totalDownloads:3175,totalCrossrefCites:17,totalDimensionsCites:34,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Ahmed Bettaieb, Paulina K. Wrzal and Diana A. Averill-Bates",authors:[{id:"61148",title:"Prof.",name:"Diana",middleName:null,surname:"Averill-Bates",slug:"diana-averill-bates",fullName:"Diana Averill-Bates"},{id:"62367",title:"Dr.",name:"Ahmed",middleName:null,surname:"Bettaieb",slug:"ahmed-bettaieb",fullName:"Ahmed Bettaieb"},{id:"62368",title:"Dr.",name:"Paulina",middleName:null,surname:"K. Wrzal",slug:"paulina-k.-wrzal",fullName:"Paulina K. Wrzal"}]},{id:"43632",title:"The Importance of Cancer Cell Lines as in vitro Models in Cancer Methylome Analysis and Anticancer Drugs Testing",slug:"the-importance-of-cancer-cell-lines-as-in-vitro-models-in-cancer-methylome-analysis-and-anticancer-d",totalDownloads:4189,totalCrossrefCites:12,totalDimensionsCites:31,book:{slug:"oncogenomics-and-cancer-proteomics-novel-approaches-in-biomarkers-discovery-and-therapeutic-targets-in-cancer",title:"Oncogenomics and Cancer Proteomics",fullTitle:"Oncogenomics and Cancer Proteomics - Novel Approaches in Biomarkers Discovery and Therapeutic Targets in Cancer"},signatures:"Daniela Ferreira, Filomena Adega and Raquel Chaves",authors:[{id:"155129",title:"Prof.",name:"Raquel",middleName:null,surname:"Chaves",slug:"raquel-chaves",fullName:"Raquel Chaves"},{id:"157394",title:"M.Sc.",name:"Daniela",middleName:"Perneta",surname:"Ferreira",slug:"daniela-ferreira",fullName:"Daniela Ferreira"},{id:"157395",title:"Dr.",name:"Filomena",middleName:null,surname:"Adega",slug:"filomena-adega",fullName:"Filomena Adega"}]},{id:"56652",title:"Heavy Metals and Cancer",slug:"heavy-metals-and-cancer",totalDownloads:1205,totalCrossrefCites:3,totalDimensionsCites:3,book:{slug:"cancer-causing-substances",title:"Cancer Causing Substances",fullTitle:"Cancer Causing Substances"},signatures:"Austin Carver and Vincent S. Gallicchio",authors:[{id:"169299",title:"Dr.",name:"Vincent",middleName:null,surname:"Gallicchio",slug:"vincent-gallicchio",fullName:"Vincent Gallicchio"},{id:"215100",title:"Mr.",name:"Austin",middleName:null,surname:"Carver",slug:"austin-carver",fullName:"Austin Carver"}]},{id:"42057",title:"Conventional Cancer Treatment",slug:"conventional-cancer-treatment",totalDownloads:1917,totalCrossrefCites:2,totalDimensionsCites:4,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Isabella dos Santos Guimarães*, Renata Dalmaschio Daltoé*, Alice\nLaschuk Herlinger, Klesia Pirola Madeira, Taciane Ladislau, Iuri\nCordeiro Valadão, Paulo Cilas Morais Lyra Junior, Sarah Fernandes\nTeixeira, Gustavo Modesto Amorim, Diandra Zipinotti dos Santos,\nKarina Rangel Demuth and Leticia Batista Azevedo Rangel",authors:[{id:"60339",title:"Prof.",name:"Renata",middleName:null,surname:"Dalto�",slug:"renata-dalto",fullName:"Renata Dalto�"},{id:"60359",title:"Dr.",name:"Letícia",middleName:null,surname:"Rangel",slug:"leticia-rangel",fullName:"Letícia Rangel"},{id:"96614",title:"Dr.",name:"Klesia",middleName:"Pirola",surname:"Madeira",slug:"klesia-madeira",fullName:"Klesia Madeira"},{id:"96615",title:"MSc.",name:"Alice",middleName:null,surname:"Herlinger",slug:"alice-herlinger",fullName:"Alice Herlinger"},{id:"165908",title:"BSc.",name:"Taciane",middleName:null,surname:"Ladislau",slug:"taciane-ladislau",fullName:"Taciane Ladislau"},{id:"165909",title:"BSc.",name:"Isabella",middleName:null,surname:"Guimarães",slug:"isabella-guimaraes",fullName:"Isabella Guimarães"},{id:"165910",title:"Ms.",name:"Sarah",middleName:null,surname:"Teixeira",slug:"sarah-teixeira",fullName:"Sarah Teixeira"},{id:"165911",title:"Mr.",name:"Paulo",middleName:null,surname:"Lyra-Junior",slug:"paulo-lyra-junior",fullName:"Paulo Lyra-Junior"},{id:"165912",title:"Mr.",name:"Iuri",middleName:null,surname:"Valadão",slug:"iuri-valadao",fullName:"Iuri Valadão"},{id:"165918",title:"MSc.",name:"Gustavo",middleName:null,surname:"Amorim",slug:"gustavo-amorim",fullName:"Gustavo Amorim"},{id:"165919",title:"Ms.",name:"Diandra",middleName:null,surname:"Santos",slug:"diandra-santos",fullName:"Diandra Santos"},{id:"165920",title:"Dr.",name:"Karina",middleName:"Rangel",surname:"Demuth",slug:"karina-demuth",fullName:"Karina Demuth"}]},{id:"34380",title:"Monocyte Subsets and Their Role in Tumor Progression",slug:"monocyte-subsets-and-their-role-in-tumor-progression",totalDownloads:3261,totalCrossrefCites:3,totalDimensionsCites:5,book:{slug:"tumor-microenvironment-and-myelomonocytic-cells",title:"Tumor Microenvironment and Myelomonocytic Cells",fullTitle:"Tumor Microenvironment and Myelomonocytic Cells"},signatures:"Andrea Doseff and Arti Parihar",authors:[{id:"92127",title:"Dr",name:"Andrea",middleName:null,surname:"Doseff",slug:"andrea-doseff",fullName:"Andrea Doseff"},{id:"127683",title:"Dr.",name:"Arti",middleName:null,surname:"Parihar",slug:"arti-parihar",fullName:"Arti Parihar"}]},{id:"44365",title:"Immunotherapy of Urinary Bladder Carcinoma: BCG and Beyond",slug:"immunotherapy-of-urinary-bladder-carcinoma-bcg-and-beyond",totalDownloads:1963,totalCrossrefCites:4,totalDimensionsCites:13,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Yi Luo, Eric J. Askeland, Mark R. Newton, Jonathan R. Henning and\nMichael A. O’Donnell",authors:[{id:"46467",title:"Prof.",name:"Yi",middleName:null,surname:"Luo",slug:"yi-luo",fullName:"Yi Luo"},{id:"95257",title:"Dr.",name:"Jonathan",middleName:null,surname:"Henning",slug:"jonathan-henning",fullName:"Jonathan Henning"},{id:"95258",title:"Prof.",name:"Michael",middleName:null,surname:"O'Donnell",slug:"michael-o'donnell",fullName:"Michael O'Donnell"},{id:"155748",title:"Dr.",name:"Eric",middleName:null,surname:"Askeland",slug:"eric-askeland",fullName:"Eric Askeland"},{id:"155749",title:"Dr.",name:"Mark",middleName:null,surname:"Newton",slug:"mark-newton",fullName:"Mark Newton"}]},{id:"41975",title:"Targeted Cancer Therapy by Dendritic Cell Vaccine",slug:"targeted-cancer-therapy-by-dendritic-cell-vaccine",totalDownloads:2202,totalCrossrefCites:0,totalDimensionsCites:2,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Hiroyuki Abe, Touko Shimamoto, Shinichiro Akiyama and Minako\nAbe",authors:[{id:"62629",title:"Prof.",name:"Hiroyuki",middleName:null,surname:"Abe",slug:"hiroyuki-abe",fullName:"Hiroyuki Abe"}]},{id:"43863",title:"Definitive Chemo-Radiotherapy for Resectable Esophageal Cancer — Unresolved Problems Remain",slug:"definitive-chemo-radiotherapy-for-resectable-esophageal-cancer-unresolved-problems-remain",totalDownloads:1398,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Shouji Shimoyama",authors:[{id:"59239",title:"Dr.",name:"Shouji",middleName:null,surname:"Shimoyama",slug:"shouji-shimoyama",fullName:"Shouji Shimoyama"}]},{id:"44356",title:"Supportive and Palliative Care in Solid Cancer Patients",slug:"supportive-and-palliative-care-in-solid-cancer-patients",totalDownloads:1370,totalCrossrefCites:0,totalDimensionsCites:0,book:{slug:"cancer-treatment-conventional-and-innovative-approaches",title:"Cancer Treatment",fullTitle:"Cancer Treatment - Conventional and Innovative Approaches"},signatures:"Bassam Abdul Rasool Hassan, Zuraidah Binti Mohd Yusoff,\nMohamed Azmi Hassali and Saad Bin Othman",authors:[{id:"155124",title:"Dr.",name:"Bassam",middleName:"Abdul Rasool",surname:"Hassan",slug:"bassam-hassan",fullName:"Bassam Hassan"}]}],onlineFirstChaptersFilter:{topicSlug:"medical-oncology",limit:3,offset:0},onlineFirstChaptersCollection:[],onlineFirstChaptersTotal:0},preDownload:{success:null,errors:{}},aboutIntechopen:{},privacyPolicy:{},peerReviewing:{},howOpenAccessPublishingWithIntechopenWorks:{},sponsorshipBooks:{sponsorshipBooks:[{type:"book",id:"10176",title:"Microgrids and Local Energy Systems",subtitle:null,isOpenForSubmission:!0,hash:"c32b4a5351a88f263074b0d0ca813a9c",slug:null,bookSignature:"Prof. Nick Jenkins",coverURL:"https://cdn.intechopen.com/books/images_new/10176.jpg",editedByType:null,editors:[{id:"55219",title:"Prof.",name:"Nick",middleName:null,surname:"Jenkins",slug:"nick-jenkins",fullName:"Nick Jenkins"}],equalEditorOne:null,equalEditorTwo:null,equalEditorThree:null,productType:{id:"1",chapterContentType:"chapter"}}],offset:8,limit:8,total:1},route:{name:"profile.detail",path:"/profiles/126074/friderike-oehler",hash:"",query:{},params:{id:"126074",slug:"friderike-oehler"},fullPath:"/profiles/126074/friderike-oehler",meta:{},from:{name:null,path:"/",hash:"",query:{},params:{},fullPath:"/",meta:{}}}},function(){var e;(e=document.currentScript||document.scripts[document.scripts.length-1]).parentNode.removeChild(e)}()